Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Cardiovascular Risk Assessment in Primary Prevention

BuchGebunden
513 Seiten
Englisch
Springererschienen am27.05.20221st ed. 2022
This book is the first comprehensive text dedicated to risk assessment in the primary prevention of atherosclerotic cardiovascular disease. It provides an overview of current evidence regarding approaches to risk assessment, traditional and emerging risk factors, and atherosclerosis imaging for refinement of risk estimation.mehr
Verfügbare Formate
BuchGebunden
EUR235,39
BuchKartoniert, Paperback
EUR165,84
E-BookPDF1 - PDF WatermarkE-Book
EUR85,59

Produkt

KlappentextThis book is the first comprehensive text dedicated to risk assessment in the primary prevention of atherosclerotic cardiovascular disease. It provides an overview of current evidence regarding approaches to risk assessment, traditional and emerging risk factors, and atherosclerosis imaging for refinement of risk estimation.
Details
ISBN/GTIN978-3-030-98823-4
ProduktartBuch
EinbandartGebunden
Verlag
Erscheinungsjahr2022
Erscheinungsdatum27.05.2022
Auflage1st ed. 2022
ReiheContemporary Cardiology
Seiten513 Seiten
SpracheEnglisch
IllustrationenXV, 513 p. 91 illus., 75 illus. in color.
Artikel-Nr.50466348
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
Part 1 - Global Approaches to Risk Assessment.- 1. Cardiovascular Risk Assessment in Primary Prevention.- 2. Global Approaches to Risk Assessment - the U.S. Guidelines.- 3. European Guidelines for Risk Assessment in the Primary Prevention of Cardiovascular Disease.- Part 2 - Traditional Risk Factors.- 4. Hypercholesterolemia.- 5. Blood pressure control in primary care.- 6. Cardiovascular Risk Assessment in Metabolic Syndrome and Diabetes.- 7. Primary Prevention: Smoking.- 8. At the Heart of the Matter: Obesity and its Interplay with Preventive Cardiology.- Part 3 - Risk Enhancers.- 9. Family History of Premature Atherosclerotic Cardiovascular Disease.- 10. Primary Prevention and Cardiovascular Risk Assessment in Women.- 11. Ethnic Factors in the Assessment of Cardiovascular Risk for Primary Prevention.- 12. Triglycerides Rich-Lipoproteins.- 13. "Inflammatory Diseases and Risk of Atherosclerotic Cardiovascular Disease: A New Focus for Prevention".- 14. Chronic Kidney Disease is a Risk Enhanced for Cardiovascular Diseases.- 15. Peripheral Arterial Disease and The Ankle Brachial Index.- Part 4 - Novel Risk Factors.- 16. Lipoprotein(a).- 17. High-Sensitivity C-Reactive Protein.- 18. Apolipoprotein B in Primary Prevention: Ready for Time Prime?.- 19. Social Determinants of Cardiovascular Health.- 20. Stress and Cardiovascular Disease.- 21. Polygenic Risk Scores.- Part 5 - Atherosclerosis Imaging as a Tool to Refine Risk Estimates.- 22. Coronary Artery Calcium.- 23. Cardiac Computed Tomography Angiography for Prevention of Cardiovascular Events.- 24. Carotid Intima-Media Thickness and Plaque Assessment.mehr

Schlagworte

Autor


Michael Shapiro  is the inaugural Fred M. Parrish Professor of Cardiology and Molecular Medicine at Wake Forest University where he is on faculty in the Section of Cardiovascular Medicine. After completing a cardiology fellowship, Michael spent two additional years in a clinical and research fellowship focused on advanced cardiovascular imaging at Massachusetts General Hospital/Harvard Medical School.  After training, he was on faculty in the Knight Cardiovascular Institute at Oregon Health & Science University. He served as Director of Atherosclerosis Imaging and Associate Director of the Center for Preventive Cardiology. In 2019, he transitioned to Wake Forest University where he serves as the Director of the Center for Prevention of Cardiovascular Disease and the Co-Director of the NIH T32 Cardiovascular Disease Epidemiology and Prevention Research Fellowship Program.

Michael's clinical interests revolve around genetic and acquired disorders of cholesterol and triglycerides, atherosclerosis imaging, genetic predisposition to early myocardial infarction, and cardiovascular risk assessment. Michael has published extensively in the areas of atherosclerosis imaging, lipid disorders, and preventive cardiology. The scope of his research spans translational science, cardiovascular epidemiology, and clinical trials of novel lipid modulating therapeutics. He also serves as a principal investigator on numerous clinical trials testing novel lipid modulating therapeutics.

Weitere Artikel von
Herausgegeben:Shapiro, Michael D.